Figure 2

Characterization of cannabinoid-induced seizures and JWH-018 pharmacokinetics. (A) Total seizing duration (i.e., the period during which electrographic seizure spikes were apparent) for ∆⁹-THC (10 mg/kg) and JWH-018 (2.5 mg/kg) (**p = 0.0003). (B) EEG spike frequency for ∆⁹-THC, 10 mg/kg and JWH-018, 2.5 mg/kg (**p = 0.003). In (A,B) spike threshold 40–50%; only high-amplitude spikes were included in the analysis. Group comparison was done using the unpaired t-test. (C) JWH-018 administration induced seizure EEG in a dose-dependent manner (**p = 0.008; *p = 0.044, assessed by one-way ANOVA and LSD post-hoc analysis). The period analysed in (B,C) was from 0 to 2 h after i.p. administration of ∆⁹-THC or JWH-018. (D,E) Pharmacokinetics of JWH-018 (D) and its main metabolites (E) in serum. (A–C) n = 6, (D,E) n = 3.